

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

Changes in the board of directors of NeuroSearch A/S

At the Annual General Meeting of NeuroSearch A/S to be held on 30 April 2008, NeuroSearch's board of directors proposes re-election of President & CEO Thomas Hofman-Bang, President & CEO Torbjörn Bjerke and CEO Allan Andersen.

Further, the board of directors proposes election of Dr. Anders Ullman, Executive Vice President, Research & Development, of Nycomed and Dr. Gerard Van Odijk, Group Vice President Europe and President & CEO of Teva Pharmaceuticals Europe, as new members of the board of directors. Both candidates have several years of experience from various leading positions in the international pharmaceutical industry. For further description of Dr. Ullman and Dr. Van Odijk, please see NeuroSearch's notice convening Annual General Meeting to be published today.

Former President & CEO of NeuroSearch Jørgen Buus Lassen will resign from the board of directors together with Attorney-at-Law Marianne Philip and CEO Asger Aamund.

An election of employee representatives to the board of directors has also been held in NeuroSearch: Lars Siim Madsen and Torben Skov were re-elected and Mads Peder Gersdorff Korsgaard was elected as a new member of the board of directors. The three employee representatives will become members of the board of directors after the Annual General Meeting.

Upon adoption by the shareholders, the board of directors will be as follows:

President & CEO Thomas Hofman-Bang (chairman)
CEO Allan Andersen
President & CEO Torbjörn Bjerke
EVP Anders Ullman
Group V.P., President & CEO Gerard van Odijk
Lars Siim Madsen (elected by the employees)
Torben Skov (elected by the employees)
Mads Peder Gersdorff Korsgaard (elected by the employees)

Asger Aamund, chairman of the board of directors, says:

"Today, NeuroSearch stands as a well-consolidated company with an important international development potential. Following the previous changes to the company's executive management, the board of directors have found it appropriate and timely to propose to our shareholders similar changes to the board of directors for adoption at the coming Annual General Meeting."

Asger Aamund
Chairman of the board of directors

Contact persons:

Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone: +45 4460 8212 or +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK, ACR343 in Parkinson's disease (Phase I) and NSD-788 in anxiety a.o. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.